Efficient identification of novel HLA-A*0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis

Journal of Experimental Medicine

Volumn 193, Issue 1, 2001, Pages 73-88

  Kessler, J H ^a   Beekman, N J ^a   Bres Vloemans, S A ^a   Verdijk, P ^a   Van Veelen, P A ^a   Kloosterman Joosten, A M ^a   Vissers, D C J ^a   Ten Bosch, G J A ^a   Kester, M G D ^a   Sijts, A ^a   Drijfhout, J W ^a   Ossendorp, F ^a   Offringa, R ^a   Melief, C J M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antigen presentation; Antigen processing; Cytotoxic T lymphocyte induction; Human histocompatibility leukocyte antigen class I binding; Tumor immunotherapy

Indexed keywords

EPITOPE; HLA A ANTIGEN; HLA ANTIGEN CLASS 1; PROTEASOME; TUMOR ANTIGEN;

ANTIGEN BINDING; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; BINDING AFFINITY; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CARBOXY TERMINAL SEQUENCE; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; IMMUNOTHERAPY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PROCESSING;

AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; BASE SEQUENCE; CELL LINE, TRANSFORMED; CYSTEINE ENDOPEPTIDASES; CYTOTOXICITY, IMMUNOLOGIC; DNA PRIMERS; EPITOPES; HLA-A ANTIGENS; HUMANS; MOLECULAR SEQUENCE DATA; MULTIENZYME COMPLEXES; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN BINDING; RNA, MESSENGER; RNA, NEOPLASM; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 0035182192     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.193.1.73     Document Type: Article

References (80)

1. Strategies for immunotherapy of cancer
2. Vaccination of patients with B-cell lymphoma using autologous antigenpulsed dendritic cells
3. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
4. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1
5. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma
6. Adoptive immunotherapy with donor lymphocyte transfusions
7. Design and evaluation of antigen-specific vaccination strategies against cancer
8. A new era for cancer immunotherapy based on the genes that encode cancer antigens
9. T cell defined tumor antigens
10. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma
11. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E
12. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma
13. BAGE: A new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes
14. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas
15. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas
16. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor
17. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes
18. A MAGE-1-encoded HLA-A24-binding synthetic peptide induces specific anti-tumor cytotoxic T lymphocytes
19. The multi-epitope approach for immunotherapy for cancer: Identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors
20. Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes
21. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3
22. A peptide encoded by the human MAGE3 gene and presented by HLA-B44 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE3
23. Induction of antitumor cytotoxic T lymphocytes with a MAGE-3-encoded synthetic peptide presented by human leukocytes antigen-A24
24. Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2)
25. Identification of subdominant CTL epitopes of the GP100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells
26. Induction and characterization of cytotoxic T-lymphocytes recognizing a mutated p21ras peptide presented by HLA-A*0201
27. p53, a potential target for tumor-directed T cells
28. T cell epitopes encompassing the mutational hot spot position 61 of p21 ras. Promiscuity in ras peptide binding to HLA
29. In vitro generation of human cytolytic T-cells specific for peptides derived from the HEP-2/neu protooncogene protein
30. Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu1 tumors
31. Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by In vitro stimulation with dendritic cells transduced with MAGE-A1
32. Antigen processing and presentation by the class I major histocompatibility complex
33. Mechanisms of MHC class I-restricted antigen processing
34. Two distinct proteolytic processes in the generation of a major histocompatibility complex class I-presented peptide
35. Promiscuous liberation of MHC-class I-binding peptides from the C termini of membrane and soluble proteins in the secretory pathway
36. Distinct proteolytic processes generate the C and N termini of MHC class I-binding peptides
37. Abrogation of CTL epitope processing by single amino acid substitution flanking the C-terminal proteasome cleavage site
38. Trimming of antigenic peptides in an early secretory compartment
39. Trimming of TAP-translocated peptides in the endoplasmic reticulum and in the cytosol during recycling
40. Processing of major histocompatibility class I-restricted antigens in the endoplasmic reticulum
41. The protease inhibitor, N-acetyl-L-leucyl-L-leucyl-leucyl-L-norleucinal, decreases the pool of major histocompatibility complex class I-binding peptides and inhibits peptide trimming in the endoplasmic reticulum
42. Interferon-gamma can stimulate post-proteasomal trimming of the N terminus of an antigenic peptide by inducing leucine aminopeptidase
43. Proteolytic processing of ovalbumin and beta-galactosidase by the proteasome to a yield antigenic peptides
44. The cleavage preference of the proteasome governs the yield of antigenic peptides
45. Contribution of proteasome-mediated proteolysis to the hierarchy of epitopes presented by major histocompatibility complex class I molecules
46. The proteolytic fragments generated by vertebrate proteasomes: Structural relationships to major histocompatibility complex class I binding peptides
47. A single residue exchange within a viral CTL epitope alters proteasome-mediated degradation resulting in lack of antigen presentation
48. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor
49. PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells
50. Heterogeneous expression of the tumor-associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma: Candidates for T-cell-based inmmnotherapies?
51. The cancer germ-line genes MAGE-1, MAGE-3 and PRAME are commonly expressed by human myeloma cells
52. Allele and haplotype frequencies for HLA and complement loci in various ethnic groups
53. Fas ligation induces apoptosis of CD40-activated human B lymphocytes
54. An HLA class I peptide-binding assay based on competition for binding to class I molecules on intact human B cells. Identification of conserved HIV-1 polymerase peptides binding to HLA-A*0301
55. Definition of a minimal optimal cytotoxic T-cell epitope within the hepatitis B virus nucleocapsid protein
56. Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability
57. The interferon-inducible 11S regulator (PA28) and the LMP2/LMP7 subunits govern the peptide production by the 20S proteasome in vitro
58. Phenotype-dependent differences in proteasome subunit composition and cleavage specificity in B cell lines
59. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α
60. CD40-activated human B cells: An alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy
61. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation
62. A computer program for predicting possible cytotoxic T lymphocyte epitopes based on HLA class I peptide-binding motifs
63. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains
64. Hairy cell leukemia-specific recognition by multiple autologous HLA-DQ or DP-restricted T-cell clones
65. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses
66. Presentation of the Goodpasture autoantigen to CD4 T cells is influenced more by processing constraints than by HLA class II peptide binding preferences
67. A theoretical approach towards the identification of cleavage-determining amino acid motifs of the 20 S proteasome
68. An algorithm for the prediction of proteasomal cleavages
69. Processing of some anti-gens by the standard proteasome but not by the immnunoproteasome results in poor presentation by dendritic cells
70. Overexpression of the proteasome subunits LMP2, LMP7, and MECL-1, but not PA28alpha/beta, enhances the presentation of an immunodominant lymphocytic chonomeningitis virus T cell epitope
71. Efficient generation of a hepatitis B virus cytotoxic T lymphocyte epitope requires the structural features of immunoproteasomes
72. MHC class I antigen processing of an adenovirus CTL epitope is linked to the levels of immunoproteasomes in infected cells
73. Differential influence on cytotoxic T lymphocyte epitope presentation by controlled expression of either proteasome immunosubunits or PA28
74. Interferon γ stimulation modulates the proteolytic activity and cleavage site preference of 20S mouse proteasomes
75. The specificity of proteasomes: Impact on MHC class I processing and presentation of antigens
76. The major substrates for TAP in vivo are derived from newly synthesized proteins
77. Cytotoxic T lymphocyte epitopes of HIV-1 Nef: Generation of multiple definitive major histocompatibility complex class I ligands by proteasomes
78. MAGE-1 expression threshold for the lysis of melanoma cell lines by a specific cytotoxic T lymphocyte
79. Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes